FGF21 and metabolic dysfunction-associated steatohepatitis: Studies conducted on rodents or on primates demonstrated that the administration of FGF21 brings considerable pharmacological benefits on a cluster of obesity-related metabolic complications, including a reduction in fat mass and alleviation of hyperglycemia, insulin resistance, dyslipidemia, cardiovascular disorders and non- alcoholic steatohepatitis (NASH).